RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studi…

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
Yahoo Finance

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Potential high value and de-risked development pathway: Existing human safety and tolerability data from over 470 subjects, from several clinical programs, may help expedite the FDA pathway to ...
Healio

Opaganib plus standard of care for severe COVID-19 reduces mortality

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Opaganib significantly reduced mortality and improved ...
News Medical

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under ...
Business Insider

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results of ...
News Medical

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of ...
EurekAlert!

RedHill accelerates Opaganib’s nuclear radiation protection program - Positive data published

Strong preclinical data, published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo studies, supports opaganib’s potential as a nuclear radiation injury ...
Nasdaq

RedHill Biopharma’s opaganib shows radioprotective activity in study

RedHill Biopharma (RDHL) announced positive results from new in vivo studies of opaganib as a treatment for gastrointestinal acute radiation syndrome, or GI-ARS, undertaken as part of the U.S.
Nasdaq

RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program

The National Institutes of Health's (NIH) Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for testing via their radiation medical countermeasures Product Development Support ...
WTVD

Biopharma with US headquarters in Raleigh touts possible drug to treat COVID-19

RALEIGH (WTVD) -- We've heard a lot lately about vaccine trials and emergency use authorization for COVID-19 vaccines. But the vaccine won't help those who are already infected and struggling to ...
EurekAlert!

RedHill announces presentation of positive oral opaganib phase 2 data in COVID-19

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of the positive ...

RedHill Biopharma Ltd.: RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical ...

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] ...